Skip to main content

Human VEGFR2/KDR/Flk-1 PE-conjugated Antibody

R&D Systems, part of Bio-Techne | Catalog # FAB357P

R&D Systems, part of Bio-Techne

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human, Mouse, Primate - Macaca fascicularis (Crab-eating Monkey or Cynomolgus Macaque), Primate - Macaca nemestrina (Southern Pig-tailed Macaque)

Applications

Validated:

Flow Cytometry

Cited:

Cell Selection, Flow Cytometry, Immunocytochemistry, Neutralization, Western Blot

Label

Phycoerythrin (Excitation = 488 nm, Emission = 565-605 nm)

Antibody Source

Monoclonal Mouse IgG1 Clone # 89106

Product Specifications

Immunogen

S. frugiperda insect ovarian cell line Sf 21-derived recombinant human VEGF R2/KDR/Flk-1
Ala20-Glu764
Accession # P35968

Specificity

Detects human VEGF R2/KDR/Flk-1 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) VEGF R1, rhVEGF R3 or recombinant mouse VEGF R2 is observed.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Scientific Data Images for Human VEGFR2/KDR/Flk-1 PE-conjugated Antibody

Detection of VEGF R2/KDR/Flk-1 antibody in HUVEC Human Cells antibody by Flow Cytometry.

Detection of VEGF R2/KDR/Flk‑1 in HUVEC Human Cells by Flow Cytometry.

HUVEC human umbilical vein endothelial cells were stained with Mouse Anti-Human VEGF R2/KDR/Flk-1 PE-conjugated Mono-clonal Antibody (Catalog # FAB357P, filled histogram) or isotype control antibody (Catalog # IC002P, open histogram). View our protocol for Staining Membrane-associated Proteins.
Detection of Human VEGFR2/KDR/Flk-1 by Flow Cytometry

Detection of Human VEGFR2/KDR/Flk-1 by Flow Cytometry

Circulating EPC number in healthy controls and diabetes. a and b: Circulating EPC numbers were determined by flow cytometry for the co-expression of CD34 and VEGFR2 (b). Peripheral blood MNCs incubated with IgG isotype control (a) serve as a negative control to determine the intrinsic fluorescent intensity of the peripheral blood MNCs and to define positive area R2. c: Absolute number of circulating EPCs in healthy controls and diabetes as determined by the co-expression of CD34 and VEGFR2. d: Absolute number of circulating EPCs in healthy controls, diabetes with good and poor glycemic control as determined by the co-expression of CD34 and VEGFR2. e: Correlation between the circulating EPC numbers and FBS, f: Correlation between the circulating EPC numbers and HbA1C, g: Absolute number of circulating CD34+/VEGFR2- cells in healthy controls and diabetes. Data are presented as means ± SEM. Image collected and cropped by CiteAb from the following publication (https://bmcendocrdisord.biomedcentral.com/articles/10.1186/1472-6823-10-5), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human VEGFR2/KDR/Flk-1 by Flow Cytometry

Detection of Human VEGFR2/KDR/Flk-1 by Flow Cytometry

Phenotypic characterization of cultured PACs. A) PACs were characterized for surface marker expression by flow cytometry. In the side scatted (SSC) versus forward scatter (FSC) morphologic plot, lymphocytic cells (LYMPHs) and monocyte-macrophages (MONOs) were identified and gated separately. Histograms reporting the expression of relevant leukocyte (CD45, CD14, CD68) and endothelial markers (CD31, KDR, CD34) are shown, together with mean percent expression from 3 replicates. The red line indicates negative control, while the blue line indicates the stained condition. B) Cells in the PACs culture were stained with the endothelial markers acLDL and Ulex Lectin. The fraction of cells that were positive for both markers were compared in cultures obtained from T2D or healthy control cells. *p < 0.05 T2D vs Ctrl. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/24886621), licensed under a CC-BY license. Not internally tested by R&D Systems.

Applications for Human VEGFR2/KDR/Flk-1 PE-conjugated Antibody

Application
Recommended Usage

Flow Cytometry

10 µL/106 cells
Sample: HUVEC human umbilical vein endothelial cells

Reviewed Applications

Read 5 reviews rated 3.8 using FAB357P in the following applications:

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Formulation

Supplied in a saline solution containing BSA and Sodium Azide.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Protect from light. Do not freeze.
  • 12 months from date of receipt, 2 to 8 °C as supplied.

Background: VEGFR2/KDR/Flk-1

VEGF R2 (KDR/Flk-1), VEGF R1 (Flt-1) and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGF R1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis. Mature VEGF R2 is composed of a 745 aa extracellular domain, a 25 aa transmembrane domain and a 567 aa cytoplasmic domain. In contrast to VEGF R1 which binds both PlGF and VEGF with high affinity, VEGF R2 binds VEGF but not PlGF with high affinity. The recombinant soluble VEGF R2/Fc chimera binds VEGF with high affinity and is a potent VEGF antagonist.

References

  1. Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.

Long Name

Vascular Endothelial Growth Factor Receptor 2

Alternate Names

CD309, Flk-1, Flk1, KDR, KRD1, Ly73, VEGF R2

Entrez Gene IDs

3791 (Human); 16542 (Mouse)

Gene Symbol

KDR

UniProt

Additional VEGFR2/KDR/Flk-1 Products

Product Documents for Human VEGFR2/KDR/Flk-1 PE-conjugated Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human VEGFR2/KDR/Flk-1 PE-conjugated Antibody

For research use only

Loading...
Loading...
Loading...
Loading...
Loading...